Antibodies News and Research

RSS

RAZCER (Rapid Astrazeneca and CARO Evaluation of Radio-modifiers) awards announced - five Canadians win

Five leading Canadian radiation oncologists receive RAZCER Awards of $22,727 each for novel studies of radiation-drug interactions that have the potential to either protect normal tissues or sensitize tumours, and thus to enhance the effectiveness of radiation therapy for cancer patients. A selection committee of members of the Canadian Association of Radiation Oncology (CARO) selected the 2011 recipients from among a field of 12 applicants. Astrazeneca provides the funds for the RAZCER Award as an educational grant.

13 Oct 2011

AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01

The Michael J. Fox Foundation (MJFF) today announced that it has awarded $1.5 million to AFFiRiS AG, a Vienna, Austria-based biotech company, for a clinical study of AFFITOPE PD01, a first-of-its-kind Parkinson's disease (PD) vaccine.

12 Oct 2011

Novel link between cell surface sugars, Darwinian sexual selection, and immune function

Researchers at the University of California, San Diego School of Medicine say that losing the ability to make a particular kind of sugar molecule boosted disease protection in early hominids, and may have directed the evolutionary emergence of our ancestors, the genus Homo.

11 Oct 2011

X-BODY, TRL enter collaboration to identify therapeutic target epitopes

X-BODY, Inc., a developer of monoclonal antibody therapeutics, today announced a partnership with Tanabe Research Laboratories U.S.A., Inc. (TRL). The companies will collaborate to identify therapeutic target epitopes and develop monospecific and/or bispecific antibodies to the identified therapeutic targets.

4 Oct 2011

DNA primer vaccine enhances immune response to H5N1 avian influenza vaccine

The immune response to an H5N1 avian influenza vaccine was greatly enhanced in healthy adults if they were first primed with a DNA vaccine expressing a gene for a key H5N1 protein, researchers say.

4 Oct 2011

GeoVax completes enrollment for HIV/AIDS vaccine Phase 2a clinical trial

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today the completion of enrollment for a Phase 2a clinical trial testing its HIV/AIDS vaccine.

3 Oct 2011

UAB Comprehensive Cancer Center receives NCI grant to renew support for cancer research program

The University of Alabama at Birmingham Comprehensive Cancer Center has received a five-year, $27.5 million Cancer Center Support Grant from the National Cancer Institute to renew support for its cancer research program through 2016.

1 Oct 2011

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

The work of a team of scientists at Cold Spring Harbor Laboratory (CSHL) led by Professor Nicholas Tonks FRS, suggests a way to overcome one of the major technical obstacles preventing a leading therapeutic target for diabetes and obesity from being addressed successfully by novel drugs.

30 Sep 2011

AnaptysBio awarded DARPA contract extension for additional high affinity thermally stable antibodies

AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that the Defense Advanced Research Projects Agency (DARPA) has extended its contract with AnaptysBio to generate additional high affinity thermally stable antibodies for biodefense applications. This extension was awarded based upon the successful completion by AnaptysBio of milestones during the first year of the contract.

30 Sep 2011

New technique helps identify how RNA molecules control gene expression

A new technique developed by researchers at the Stanford University School of Medicine allows researchers to identify the exact DNA sequences and locations bound by regulatory RNAs. This information is necessary to understand how the recently identified RNA molecules control the expression of neighboring and distant genes.

30 Sep 2011

Powerful HIV vaccine being tested on humans

Spanish researchers have developed a prototype of a vaccine against the AIDS-causing HIV virus that is “much more powerful” than those made to date.

29 Sep 2011

Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV

Phase I clinical trials developed by Spanish Superior Scientific Research Council (CSIC) together with Gregorio Mara--n Hospital in Madrid and Cl-nic Hospital in Barcelona, reveals MVA-B preventive vaccine's immune efficiency against Human's immunodeficiency virus (HIV).

28 Sep 2011

University of Zurich receives AICR grant to improve vaccines against Burkitt's lymphoma

Research in Switzerland could help reduce the time taken to develop vaccines against cancer tumours.

27 Sep 2011

Study identifies genetic mutations that affect immune response to measles vaccination

Researchers at Mayo Clinic are hacking the genetic code that controls the human response to disease vaccination, and they are using this new cipher to answer many of the deep-seated questions that plague vaccinology, including why patients respond so differently to identical vaccines and how to minimize the side effects to vaccination.

23 Sep 2011

Researchers discover how a novel type of antibody works against pneumococcal bacteria

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how a novel type of antibody works against pneumococcal bacteria.

23 Sep 2011

Theraclone initiates TCN-032 Phase 1 trial in influenza A

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today first dosing of subjects in a Phase 1 clinical trial of TCN-032, a broadly protective, fully human monoclonal antibody for the treatment of influenza A virus.

22 Sep 2011

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

Silence Therapeutics Plc, a leading international RNAi therapeutics company, today provides a corporate update and announces its interim results for the six months ended 30 June 2011.

21 Sep 2011

NIH announces recipients of 2011 Transformative Research Award Projects

The National Institutes of Health has announced the recipients of the 2011 Transformative Research Award Projects. This innovative research program was established in 2009 to support exceptionally innovative, high risk, original and/or unconventional research projects, and is supported by the NIH Common Fund.

21 Sep 2011

Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data from a preclinical study evaluating the efficacy its NDV-3 vaccine in a model of vulvovaginal candidiasis (VVC), which is primarily caused by Candida albicans.

20 Sep 2011

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive Phase 1 data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

19 Sep 2011

Antibodies News and Research

RAZCER (Rapid Astrazeneca and CARO Evaluation of Radio-modifiers) awards announced - five Canadians win

AFFiRiS receives MJFF grant for clinical study of AFFITOPE PD01

Novel link between cell surface sugars, Darwinian sexual selection, and immune function

X-BODY, TRL enter collaboration to identify therapeutic target epitopes

DNA primer vaccine enhances immune response to H5N1 avian influenza vaccine

GeoVax completes enrollment for HIV/AIDS vaccine Phase 2a clinical trial

UAB Comprehensive Cancer Center receives NCI grant to renew support for cancer research program

New targeting approach to develop an active site-directed, drug-like PTP1B inhibitor

AnaptysBio awarded DARPA contract extension for additional high affinity thermally stable antibodies

New technique helps identify how RNA molecules control gene expression

Powerful HIV vaccine being tested on humans

Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV

University of Zurich receives AICR grant to improve vaccines against Burkitt's lymphoma

Study identifies genetic mutations that affect immune response to measles vaccination

Researchers discover how a novel type of antibody works against pneumococcal bacteria

Theraclone initiates TCN-032 Phase 1 trial in influenza A

Silence Therapeutics reports revenue of £354,078 for six months ended 30 June 2011

NIH announces recipients of 2011 Transformative Research Award Projects

Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

Immunology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News